Stilla Technologies
The multiplex digital PCR company, specializing in precise and accurate nucleic acid detection and quantification through its Crystal Digital PCR platform, enabling high-throughput molecular analysis.
Notes
Stilla Technologies is a biotechnology company specializing in multiplex digital PCR for precise and accurate nucleic acid detection and quantification. Founded in 2016 and headquartered in Villejuif, France, the company has developed the Crystal Digital PCR platform.
Digital PCR (dPCR) is a next-generation PCR technology that provides absolute quantification of nucleic acids without the need for standard curves. Stilla's Crystal Digital PCR platform offers:
- High multiplexing capabilities (up to 6-color detection)
- High throughput with microfluidic partitioning
- Precise absolute quantification
- Applications in oncology, infectious disease, and genetic testing
The company's technology is based on innovations in microfluidics and crystal-based partitioning.
Team
- Rémi Dangla, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/remidangla
- David Roussel - Co-founder & Chief Technology Officer
Additional Research Findings
- Crystal Digital PCR platform
- Multiplex digital PCR technology
- Microfluidic partitioning approach
- Applications in oncology, infectious disease, genetics
- Villejuif, France headquarters
- Founded in 2016
- European digital PCR leader
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |